Clinical Trial

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally Advanced Unresectable or Metastatic Pancreatic Cancer Who Received at least 2 Prior Lines of Therapy. The primary objective of this study is to determine Overall Survival (OS) of IBI343 plus best supportive care (BSC) compared with placebo plus BSC.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-04.
Status change: Not Yet Recruiting → Recruiting 2025-08-14
Trial Details
NCT Number NCT07066098
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Pancreatic Cancer
Enrollment 201 participants
Start Date 2025-08-04
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-15